The overarching objective is to develop new evidence-based treatment guidelines for invasive
fungal diseases in children. To accomplish that, this protocol will focus on two specific
aims: 1) Compare the effectiveness of echinocandin versus amphotericin B or triazole
antifungal therapy for pediatric invasive candidiasis and for the subset of patients with
invasive candidemia; 2) Characterize the incidence rate of inpatient pediatric invasive
candidiasis per hospital admissions.
Details
Lead Sponsor:
Duke University
Collaborators:
Children's Hospital of Philadelphia National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Amphotericin B Antifungal Agents Caspofungin Clotrimazole Fluconazole Liposomal amphotericin B Micafungin Miconazole Voriconazole